Can the nephron be spared?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 21451536.
- Also identified by DOI 10.1038/ki.2010.557.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The search continues for the best role for mTOR inhibitor drugs in renal transplantation-principally to avoid or minimize the nephrotoxicity of the CNI class of immunosuppressive agents. The Spare the Nephron Trial describes the popular approach of early conversion from a CNI to the mTOR agent sirolimus for patients maintained on mycophenolate mofetil and steroids. At 1-2 years the glomerular filtration rate (GFR) was superior for the sirolimus group, with a loss of tolerability for about 20%.
Medical subject headings
- Immunosuppressive Agents
- Kidney Transplantation
- Nephrons